View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
February 18, 2020

Clinical trials landscape of conjunctivitis

GlobalData analysed the number of clinical trials examining conjunctivitis with start dates between January 1, 2009 and February 13, 2020.

By GlobalData Healthcare

GlobalData analysed the number of clinical trials examining conjunctivitis with start dates between January 1, 2009 and February 13, 2020.

The most common eye disease, conjunctivitis is an optic condition where the outermost layer of the white part of the eye becomes inflamed and irritated, resulting in the eye appearing pink and sore. Symptoms include pain, burning, and itchiness. Easily prevented by handwashing, conjunctivitis is initially caused by a virus that then leads to a bacterial infection. In adults the majority of cases seem to be viral, whereas in children most cases seem to be bacterial. Both viral and bacterial conjunctivitis are resolved without any treatment, but in bacterial cases topical antibiotics may be prescribed if symptoms are severe. Antihistamines may be used to help with symptom relief.

GlobalData analysed trials that focused on conjunctivitis. Figure 1 shows that the majority of trials were in Phase II (35.7%), followed by Phase III (29.3%) and Phase I (18.1%). The least amount of trials were conducted in Phase IV at 16.7%. Seventy-seven percent of these trials had industry-led sponsors whereas non-industry sponsors accounted for 22% of trials. The US conducted the highest amount of trials at 51.7%, followed by Spain (15.3%), Germany (14.0%), India (11.8%), and Poland (7.2%) (Figure 2).

Related Companies

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU